Sponsored by

xCures

Please click on the above banner for more details

WEBSITECHANGES

You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.

Click HERE for details on RSS.

Displaying items 1 to 25 of about 5510

Website Changes

12/05/2022

CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA

12/05/2022

Our webinar with Dr Linda Liau on DcVax is tonight 12/5/22 at 8:30pm Eastern

12/02/2022

Musella Foundation Brain Tumor Copay Program now open for new and renewal applications!

12/01/2022

Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation

12/01/2022

Convection-enhanced delivery of topotecan active in glioblastoma

11/29/2022

Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

11/28/2022

Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registry

11/24/2022

Ulixertinib may change childhood brain tumor treatment

11/22/2022

The accelerated approval pathway is evolving in plain sight, with or without congressional help

11/22/2022

Musella Foundation 2022 Highlights

11/22/2022

. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA

11/22/2022

The children`s brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science

11/21/2022

DCVAX webinar: Tuesday Nov 29, 2022 at 7pm Eastern

11/19/2022

- Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry

11/19/2022

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

11/19/2022

POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRAIN CANCER PRESENTED AT THE SOCIETY FOR NEURO-ONCOLOGY 2022 ANNUAL MEETING

11/19/2022

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

11/17/2022

Association of Autologous Tumor Lysate Loaded Dendritic Cell Vaccination With Extended Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

11/17/2022

Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting

11/17/2022

Vaccine shown to prolong life of patients with aggressive brain cancer

11/16/2022

xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

11/16/2022

CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL

11/14/2022

Starving Cancer Cells Without Starving You

11/14/2022

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma

11/14/2022

Giving Tuesday Contest

Our privacy / cookie policy has changed.
Click HERE to read it!